...
首页> 外文期刊>Indian journal of pharmacology. >Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study
【24h】

Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study

机译:膝关节骨关节炎患者临床效果和安全性比较:随机,前瞻性,开放式平行群体研究

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Osteoarthritis (OA) is a chronic progressive degenerative disease of weight-bearing joints and the leading cause of disability in elderly. Current medical management of OA is mostly palliative with nonsteroidal anti-inflammatory drugs (NSAIDs) being the mainstay of therapy. Reports of gastrointestinal adverse effects with traditional NSAIDs and cardiovascular adverse effects associated with selective cyclooxygenase-2 (COX-2) inhibitors have prompted the hunt for a better NSAID with no or minimal adverse effects. This study compares the clinical effectiveness and safety of newer NSAIDS etodolac and lornoxicam to diclofenac which has been a standard therapy in patients of OA of knee joint.
机译:目的:骨关节炎(OA)是一种慢性渐进性退行性疾病的负重关节和老年人残疾原因。 目前OA的医学管理大多是姑息性的非甾体抗炎药(NSAID)是治疗的主要抗炎药。 胃肠道不良反应的报告与选择性环氧化酶-2(COX-2)抑制剂相关的传统NSAID和心血管不良反应促使捕获没有任何不良反应的更好的NSAID。 该研究比较了较新的NSAIDS eTodolac和林昔康至双氯芬酸的临床效果和安全,这是膝关节OA患者的标准治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号